Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth Factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Yang, Mengliu ^a   Dong, Jing ^a   Liu, Hua ^b   Li, Ling ^a   Yang, Gangyi ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; GLUCOSE; HUMAN INSULIN; INSULIN ASPART; FIBROBLAST GROWTH FACTOR; INSULIN;

ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CONTINUOUS INFUSION; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; SUBCUTANEOUS DRUG ADMINISTRATION;

BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FIBROBLAST GROWTH FACTORS; GLUCOSE TOLERANCE TEST; HUMANS; INFUSIONS, SUBCUTANEOUS; INSULIN; INSULIN RESISTANCE;

EID: 80055055627     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026359     Document Type: Article

References (28)

1. Bottcher RT, Niehrs C, (2005) Fibroblast growth factor signaling during early vertebrate development. Endocr Rev 26: 63-77.
2. Huang X, Yu C, Jin C, Yang C, Xie R, et al. (2006) Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog 45: 934-942.
3. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, et al. (2007) Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 27: 3417-3428.
4. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, et al. (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148: 774-781.
5. Nishimura T, Nakatake Y, Konishi M, Itoh N, (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492: 203-206.
6. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, et al. (2007) Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282: 26687-26695.
7. Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, et al. (2008) FGF21 attenuates lipolysis in human adipocytes: a possible link to improved insulin sensitivity. FEBS Lett 582: 1725-1730.
8. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, et al. (2007) Hepatic fibroblast growth factor 21 is regulated by PPARγ and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5: 426-437.
9. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, et al. (2008) FGF21 corrects obesity in mice. Endocrinology 12: 6018-6027.
10. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, et al. (2007) Endocrine regulation of the fasting response by PPAR γ-mediated induction of fibroblast growth factor 21. Cell Metab 5: 415-425.
11. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, et al. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-1635.
12. Lundasen T, Hunt MC, Nilsson LM, Sanyal S, Angelin B, et al. (2007) PPARγ is a key regulator of hepatic FGF21. Bio Bio Res Commun 360: 437-440.
13. Wente W, Efanov AM, Brenner M, Kharitonenkov A, Koster A, et al. (2006) Fibroblast growth factor-21 improves pancreatic β-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55: 2470-2478.
14. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, et al. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149: 6018-6027.
15. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58: 250-259.
16. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E, (2009) Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150: 4931-4940.
17. Chen WW, Li L, Yang GY, Li K, Qi XY, et al. (2007) Circulating FGF-21 Levels in Normal Subjects and in Newly Diagnose Patients with Type 2 Diabetes Mellitus. Exp Clin Endocrinol Diab 115: 1-4.
18. Li K, Li L, Yang M, Zong H, Liu H, et al. (2009) Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus. Eur J Endocrinol 161: 391-395.
19. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, et al. (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57: 1246-1253.
20. Dostalova I, Kavalkova P, Haluzikova D, Lacinova Z, Mraz M, et al. (2008) Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 93: 3627-3632.
21. Lormeau B, Aurousseau MH, Valensi P, Paries J, Attali JR, (1997) Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized glycemic control with continuous insulin infusion in type II diabetic patients. Metabolism 46: 1074-1079.
22. Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, et al. (2003) Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26: 2231-2237.
23. Weng J, Li Y, Xu W, Shi L, Zhang Q, et al. (2008) Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomized parallel-group trial. Lancet 371: 1753-1760.
24. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, et al. (2009) Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 32: 1542-1546.
25. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, (2010) Obesity is a fibroblast growth factor 21 (FGF-21)-resistant state. Diabetes 59: 2781-2789.
26. Alberti KG, Zimmet PZ, (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabetic Med 15: 539-553.
27. DeFronzo RA, Tobin JD, Andres R, (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214-E223.
28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.